Zentalis Pharmaceuticals (ZNTL) EBIT (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly EBIT of -$37.9 million for Q1 2026, up 17.03% year-over-year from -$32.3 million in Q1 2025, and down 1.24% quarter-over-quarter from -$37.4 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) EBIT (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' EBIT history runs 8 years deep, the most recent figure standing at -$37.9 million for Q1 2026.
- In Q1 2026, EBIT rose 17.03% year-over-year to -$37.9 million; the TTM figure through Mar 2026 stood at -$145.0 million (up 31.6% YoY), while the FY2025 annual figure was -$152.8 million, up 20.08% from the prior year.
- EBIT for Q1 2026 stood at -$37.9 million, down from -$37.4 million in the prior quarter.
- The five-year high for EBIT was -$24.8 million in Q1 2024, with the low at -$103.9 million in Q2 2023.
- The 5-year median for EBIT is -$51.8 million (2022), against an average of -$53.5 million.
- The sharpest annual moves came in 2024 and 2025: EBIT soared 61.87% in 2024, then tumbled 84.22% in 2025.
- Zentalis Pharmaceuticals' EBIT stood at -$51.8 million in 2022, then tumbled by 31.24% to -$67.9 million in 2023, then increased by 26.61% to -$49.8 million in 2024, then increased by 24.99% to -$37.4 million in 2025, then retreated by 1.24% to -$37.9 million in 2026.
- Business Quant data shows ZNTL's EBIT at -$37.9 million in Q1 2026, -$37.4 million in Q4 2025, and -$33.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | -44.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.39 Mn |
| Mar 31, 2026 | -37.86 Mn |
| Dec 31, 2025 | -37.39 Mn |
| Sep 30, 2025 | -33.73 Mn |
| Jun 30, 2025 | -36.06 Mn |
| Mar 31, 2025 | -45.62 Mn |
| Dec 31, 2024 | -49.85 Mn |
| Sep 30, 2024 | -51.43 Mn |
| Jun 30, 2024 | -65.15 Mn |
| Mar 31, 2024 | -24.77 Mn |
| Dec 31, 2023 | -67.92 Mn |
| Sep 30, 2023 | -62.72 Mn |
| Jun 30, 2023 | -103.92 Mn |
| Mar 31, 2023 | -64.95 Mn |
| Dec 31, 2022 | -51.75 Mn |
| Sep 30, 2022 | -54.19 Mn |
| Jun 30, 2022 | -63.46 Mn |
| Mar 31, 2022 | -57.88 Mn |
| Dec 31, 2021 | -48.19 Mn |
| Sep 30, 2021 | -62.87 Mn |